A Good Week For Cardiovascular Research Centers
This article was originally published in RPM Report
Executive Summary
FDA took regulatory actions related to cardiovascular outcomes trials in obesity, opioid-induced constipation, triglycerides and testosterone. But the number of new studies conducted may actually be smaller than it sounds.